OLEMA PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-162.5M | $-129.5M | $-96.7M | $-104.8M | $-71.1M | $-22.1M | $-4.3M |
| Depreciation & Amortization | $490.0K | $393.0K | $377.0K | $357.0K | $163.0K | $11.0K | $9.0K |
| Depreciation | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $17.6M | $22.6M | $17.3M | $18.8M | $15.9M | $3.1M | — |
| Net Cash from Operating Activities | $-146.7M | $-104.4M | $-83.7M | $-82.1M | $-50.7M | $-19.9M | $-3.1M |
| Investing Activities | |||||||
| Capital Expenditures | — | $159.0K | — | $363.0K | $1.6M | $56.0K | — |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-155.8M | $-93.5M | $-4.9M | $91.5M | $-275.4M | $-56.0K | — |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $211.3M | $268.8M | $133.4M | $476.0K | $1.4M | $358.4M | — |
| Net Change in Cash | $-91.2M | $70.9M | $44.8M | $9.9M | $-324.7M | $338.5M | $-3.1M |
| Free Cash Flow | — | $-104.5M | — | $-82.4M | $-52.3M | $-19.9M | — |